Protection of the patient in nuclear medicine

Adams R. (1984). Suggested revision of NEMA Standards. J. Nucl. Med. 25, 814–816.

Ahlgren L. Bjurman B. Mattsson S. (1983). Personaldoser vid hantering av ^99mTc på sjukhuset, Report a83–18. Statens Strålskyddsinstitut, Stockholm. (In Swedish.).

Ahlgren L. Ivarsson S. (1985). Excretion of radionuclides in human breast milk after the administration of radiopharmaceuticals. J. Nucl. Med. 26, 1085–1090.

AAPM (1980). Scintillation Camera Acceptance Testing and Performance Evaluation, Nuclear Medicine Committee, AAPM Report No. 6. American Institute of Physics, New York.

AAPM (1981). Computer-aided Scintillation Camera Acceptance Testing, Nuclear Medicine Committee, AAPM Report No. 9. American Institute of Physics, New York.

Beierwaltes W. H. (1985). Horizons in radionuclide therapy: 1985 update. J. Nucl. Med. 26, 421–427.

Benua R. S. Cicale N. R. (1962). The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am. J. Roentgenol. 87, 171–182.

Berk P. D. Goldberg J. D. (1981). Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. New Engl. J. Med. 304, 441–447.

Blom P. S. Querido A. (1955). Acute leukaemia following x-ray and radioiodine treatment of thyroid carcinoma. Br. J. Radiol. 28, 165–166.

Buchan R. C. T. Brindle T. M. (1971). Radionuclide therapy to outpatients—The radiation hazard. Br. J. Radiol. 44, 973–975.

Coakley J. L. Mountford P. J. (1985). Nuclear medicine and the nursing mother. Br. Med. J. 291, 159–160.

Conway J. J. (1984). Practical considerations in radionuclide imaging of pediatric patients. In: Clinical Radionuclide Imaging, Vol. 8, pp. 329–359 (eds. Freeman L. M. Johnson P. M. ), Grune and Stratton, New York.

Delarue J. Tubiana M. (1953). Cancer de la thyroïde traité par l'iode radioactif; terminaison par une leucémie aiguë après une amélioration importante. Bull. Ass. franç. Cancer 40, 263–271.

Dillman L. T. von der Lage F. C. (1975). Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation-Dose Estimation, MIRD Pamphlet No. 10. Society of Nuclear Medicine, New York.

Edmonds C. J. Smith T. (1986). The long-term hazards of the treatment of thyroid cancer with radioiodine. Br. J. Radiol. 59, 45–51.

Gelfand M. J. Thomas S. R. (1983). Absorbed radiation dose from routine imaging of the skeleton in children. Ann. Radiol. 26, 421–423.

Haanen C. Mathé G. (1981). Treatment of polycythemia vera by radiophosphorus or busulphan: A randomised trial. Br. J. Cancer 44, 75–80.

Hamilton D. R. Paras P. , (eds) (1984). Quality Assurance in Nuclear Medicine, HHS Publication FDA 84–8224. Center for Devices and Radiological Health. Superintendent of Documents. U.S. Government Printing Office, Washington, DC.

Hellström G. Malmström I. (1983). Isotopkommittérapporter 1983, SSI Report 85–15. Statens strålskyddsinstitut, Stockholm. (In Swedish.).

IAEA (1984). The Quality Control of Nuclear Medicine Instruments, Technical Document 316. IAEA, Vienna.

ICRP (1966). The Evaluation of Risks from Radiation, ICRP Publication 8. Pergamon Press, Oxford.

ICRP (1969). Radiosensitivity and Spatial Distribution of Dose, ICRP Publication 14. Pergamon Press, Oxford.

ICRP (1971). Protection of the Patient in Radionuclide Investigations, ICRP Publication 17. Pergamon Press, Oxford.

ICRP (1975). Reports of the Task Group on Reference Man, ICRP Publication 23. Pergamon Press, Oxford.

ICRP (1977). Recommendations of the International Commission on Radiological Protection, ICRP Publication 26. Pergamon Press, Oxford. Ann. ICRP 1 (3).

ICRP (1979–1981). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30, Supplements and Index. Pergamon Press, Oxford. Ann. ICRP 2, (3–4); 3, (1–4); 4, (3–4); 5, (1–6); 6, (2–3); 7, (1–3); 8, (1–4).

ICRP (1982). Protection of the Patient in Diagnostic Radiology, ICRP Publication 34. Pergamon Press, Oxford. Ann. ICRP 9 (2–3).

ICRP (1983a). Cost-Benefit Analysis in the Optimisation of Radiation Protection, ICRP Publication 37. Pergamon Press, Oxford. Ann. ICRP 10 (2–3).

ICRP (1983b). Radionuclide Transformations: Energy and Intensity of Emissions, ICRP Publication 38. Pergamon Press, Oxford. Ann. ICRP 11–13.

ICRP (1984). A Compilation of the Major Concepts and Quantities in Use by ICRP, ICRP Publication 42. Pergamon Press, Oxford. Ann. ICRP 14 (4).

ICRP (1985a). Protection of the Patient in Radiation Therapy, ICRP Publication 44. Pergamon Press, Oxford. Ann. ICRP 15 (2).

ICRP (1985b). Quantitative Bases for Developing a Unified Index of Harm, ICRP Publication 45. Pergamon Press, Oxford. Ann. ICRP 15 (3).

ICRP (1986). Developmental Effects of Irradiation on the Brain of the Embryo and Fetus, ICRP Publication 49. Pergamon Press, Oxford. Ann. ICRP 16 (4).

ICRP (1987). Radiation Dose to Patients from Radiopharmaceuticals, ICRP Publication 53. Pergamon Press, Oxford. Ann. ICRP 18 (1–4).

ICRU (1979). Methods of Assessment of Absorbed Dose in Clinical Use of Radionuclides, ICRU Publication 32. International Commission on Radiation Units and Measurements, Washington, DC.

Jelliffe A. M. Jones K. M. (1960). Leukaemia after ¹³¹I therapy of thyroid cancer. Clin. Radiol. 11, 134–135.

Joseph P. M. Hilal S. K. (1980). Clinical and experimental investigation of a smoothed CT reconstruction algorithm. Radiology 134, 507–516.

Lewallen C. G. (1963). Some observations on radiation dose to bone marrow during ¹³¹I therapy of thyroid cancer. Am. J. Roentgenol. 89, 613–623.

Mays C. W. Spiess H. (1984). Bone sarcomas in patients given ²²⁴Ra. In: Radiation Carcinogenesis: Epidemiology and Biological Significance, pp. 241–252, (eds. Boice J. D. Jr Fraumeni J. F. Jr ) Raven Press, New York.

MIRD Dose Estimate Report No. 1 (1973a). Summary of current radiation dose estimates to humans from ⁷⁵Se-L-selenomethionine. J. Nucl. Med. 14, 49–50.

MIRD Dose Estimate Report No. 2 (1973b). Summary of current radiation dose estimates to humans from ⁶⁶Ga, ⁶⁷Ga, ⁶⁸Ga and ⁷²Ga-citrate. J. Nucl. Med. 14, 755–756.

MIRD Dose Estimate Report No. 3 (1975a). Summary of current radiation dose estimates to humans with various liver conditions from ^99mTc-Sulfur colloid. J. Nucl. Med. 16, 108. A-B.

MIRD Dose Estimate Report No. 4 (1975b). Summary of current radiation dose estimates to humans with various liver conditions from ¹⁹⁸Au-colloidal gold. J. Nucl. Med. 16, 173–174.

MIRD Dose Estimate Report No. 5 (1975c). Summary of current radiation dose estimates to humans from ¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁶I, ¹³⁰I, ¹³¹I and ¹³²I as sodium iodide. J. Nucl. Med. 16, 857–860.

MIRD Dose Estimate Report No. 6 (1975d). Summary of current radiation dose estimates to humans from ¹⁹⁷Hg-and ²⁰³Hg-labelled chlormerodrin. J. Nucl. Med. 16, 1095–1098.

MIRD Dose Estimate Report No. 7 (1975e). Summary of current radiation dose estimates to humans from ¹²³I, ¹²⁴I, ¹²⁶I, ¹³⁰I and ¹³¹I as sodium Rose Bengal. J. Nucl. Med. 16, 1214–1217.

MIRD Dose Estimate Report No. 8 (1976). Summary of current radiation dose estimates to normal humans from ^99mTc as sodium pertechnetate. J. Nucl. Med. 17, 74–77.

MIRD Dose Estimate Report No. 9 (1980). Estimates of radiation absorbed doses from radioxenons in lung imaging. J. Nucl. Med. 21, 459–465.

MIRD Dose Estimate Report No. 10 (1982). Radiation absorbed dose from albumin microspheres labeled with ^99mTc. J. Nucl. Med. 23, 915–917.

MIRD Dose Estimate Report No. 11 (1983). Radiation absorbed doses from ⁵²Fe, ⁵⁵Fe and ⁵⁹Fe used to study ferrokinetics. J. Nucl. Med. 24, 339–348.

Modan B. Lilienfeld A. M. (1964). Leukaemogenic effect of ionising irradiation treatment in polycythemia. Lancet 2, 439–441.

MRC (1986). CEIR forum on the microdosimetry of radiopharmaceuticals. Int. J. Radiat. Biol. 50(3), 555–567.

NCRP (1982). Nuclear Medicine: Factors Influencing the Choice and Use of Radionuclides in Diagnosis and Therapy, NCRP Report No. 70. National Council on Radiation Protection and Measurements, Bethesda, Maryland.

NCRP (1985a). Induction of Thyroid Cancer by Ionizing Radiation, NCRP Report No. 80. National Council on Radiation Protection and Measurements, Bethesda, Maryland.

NCRP (1985b). The Experimental Basis for Absorbed-Dose Calculations in Medical Uses of Radionuclides, NCRP Report No. 83. National Council on Radiatioan Protection and Measurements, Bethesda, Maryland.

NCRP (1987). Quality Assurance in Diagnostic Radiology, Report of NCRP Scientific Committee 70. (In preparation.).

NEMA (1980). Performance Measurements of Scintillation Cameras, Standards Publication NUI-1980. National Electrical Manufacturers Association, Washington, DC.

NAS (1972). National Research Council-National Academy of Sciences. The Effects on Populations of Exposure to Low Levels of Ionizing Radiation, Report of the Advisory Committee on the Biological Effects of Ionizing Radiations. Superintendent of Documents. U.S. Government Printing Office, Washington, DC.

NAS (1980). National Research Council-National Academy of Sciences. The Effects on Populations of Exposure to Low Levels of Ionizing Radiation, Report of the Committee on the Biological Effects of Ionizing Radiations. National Academy Press, National Academy of Sciences, Washington, DC.

NIH (1985). Report of the National Institutes of Health ad hoc Working Group to Develop Radioepidemiological Tables. U.S. Government Printing Office, Washington, DC.

Nishizawa K. Ohara K. (1980). Monitoring of I excretions and used materials of patients treated with ¹³¹I. Health Phys. 38, 467–481.

Otake M. Schull W. J. (1984). In utero exposure to A-bomb radiation and mental retardation: A reassessment. Br. J. Radiol. 57, 409–414.

Ozardo A. Ergin U. (1961). Chronic myelogenous leukaemia following ¹³¹I therapy for metastatic thyroid carcinoma. Am. J. Roentgenol. 85, 914–918.

Pochin E. E. (1972). Radionuclide therapy to out-patients: The radiation hazard. Br. J. Radiol. 45, 391.

Raff U. Spitzer V. M. (1984). Practicality of NEMA performance specification measurements for user-based acceptance testing and routine quality assurance. J. Nucl. Med. 25, 679–687.

Royal H. D. McNeill B. J. (1983). Quantitative analysis in clinical nuclear medicine. In: Clinical Nuclear Medicine, pp. 457–479, (eds. Maisey N. N. ) W. B. Saunders Company, Philadelphia, Pennsylvania.

Saenger E. L. Thoma G. E. (1968). Incidence of leukemia following treatment of hyperthyroidism. J.A.M.A. 205, 855–862.

Saenger E. L. (1982). Ethics, Trade-Offs and Medical Radiation, The Lauriston S. Taylor Lecture Series in Radiation Protection and Measurements, Lecture No. 6. National Council on Radiation Protection and Measurements, Bethesda, Maryland.

Sarkar S. D. Beierwaltes W. H. (1976). Subsequent fertility and birth histories of children and adolescents treated with ¹³¹I for thyroid cancer. J. Nucl. Med. 17, 460–464.

Seidlin S. M. Siegel E. (1956). Acute myeloid leukaemia following prolonged ¹³¹I therapy for metastatic thyroid carcinoma. Science 123, 800–801.

Shore R. M. Hendee W. R. (1986). Radiopharmaceutical dosage selection for pediatric nuclear medicine. J. Nucl. Med. 27, 287–298.

Snyder W. S. Ford M. R. (1975). ‘S’, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs, MIRD Pamphlet No. 11. Society of Nuclear Medicine, New York.

Taylor D. M. (1979). Radionuclide investigations and pregnancy: Protection of the embryo and fetus. Br. J. Radiol. 52, 605–607.

Todd-Pokropek A. (1982). Quality control, detection and display. In: Radionuclide Imaging, pp. 27–76 (ed. Kuhl D. E. ) Pergamon Press, Oxford.

UNSCEAR (1972). Ionizing Radiation: Levels and Effects, United Nations Scientific Committee on the Effects of Atomic Radiation, 1972 Report to the General Assembly. United Nations Publications, Sales Nos. E.72.IX.17 and 18, New York.

UNSCEAR (1977). Sources and Effects of Ionizing Radiation, United Nations Scientific Committee on the Effects of Atomic Radiation, 1977 Report to the General Assembly. United Nations Publications, Sales No. E.77.IX.1, New York.

UNSCEAR (1982). Ionizing Radiation: Sources and Effects, United Nations Scientific Committee on the Effects of Atomic Radiation, 1982 Report to the General Assembly. United Nations Publications, Sales No. E.82.IX.8, New York.

UNSCEAR (1986). Biological Effects of Prenatal Irradiation, Annex C to the Committee's 1986 Report to the General Assembly. United Nations Publications, Sales No. E.86.IX.9, New York.

USNRC (1981). Compilation of Data on Misadministration Reports for 1981. U.S. Nuclear Regulatory Commission, Washington, DC.

Wasserman L. R. (1976). The treatment of polycythemia vera. Semin. Hematol. 13, 57–78.

Weinstein M. C. Fineberg H. V. (1980) Clinical Decision Analysis. W. B. Saunders Company, Philadelphia, Pennsylvania.

WHO (1982). Quality Assurance in Nuclear Medicine. A guide prepared following a Workshop held in Heidelberg, Federal Republic of Germany, 17–20 November 1980. World Health Organization, Geneva.

WMA (1965). Declaration of Helsinki: Recommendations guiding doctors in clinical research. WHO Chronicle 19, 19–32.